Prescription patterns demonstrate high demand for treating erectile dysfunction following radical prostatectomy

Area of Science:

• Urology
• Oncology
• Pharmacology

Background:

• Radical prostatectomy is a common treatment for prostate cancer.
• Erectile dysfunction (ED) is a significant side effect of radical prostatectomy.
• Phosphodiesterase-5 inhibitors are a primary treatment for post-prostatectomy ED.

Purpose of the Study:

• To investigate the rate of ED prescriptions following radical prostatectomy.
• To identify factors influencing ED prescription rates in this patient population.

Main Methods:

• Retrospective analysis of Danish Prostate Registry (DanProst) and Danish Prescription Registry data (1995-2021).
• Inclusion of men undergoing radical prostatectomy, active surveillance, or nonmalignant biopsies.
• Calculation of prescription proportions and odds ratios (ORs) for ED medications (ATC: G04BE).

Main Results:

• A significant increase in ED prescriptions was observed post-biopsy in men with radical prostatectomy compared to control groups.
• Men with prior ED prescriptions had a 3.49-fold increased likelihood of new prescriptions.
• Unilateral nerve-sparing surgery (OR 1.23) and no nerve-sparing surgery (OR 0.40) were associated with different prescription risks compared to bilateral nerve-sparing surgery.

Conclusions:

• High demand for ED treatment exists post-radical prostatectomy.
• Prostate cancer survivors represent a large population requiring focused clinical attention for managing ED.
• Surgical approach, specifically nerve-sparing techniques, influences ED treatment patterns.